ZIOPHARM Oncology

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event

Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley '21 Two-Day Live Virtual Educational Symposium

Annual shareholder meeting to be held on May 19, 2021 Annual shareholder meeting to be held on May 19, 2021

Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021

BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.

Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell

Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers

Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting

Shares are dropping after an analyst's downgrade.

Why Ziopharm Oncology Stock Is Sinking Today

Investors reacted positively to FDA clearance to begin a clinical study and Ziopharm's CEO change.

Why Ziopharm Oncology Stock Is Jumping Today

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2020 Results - Earnings Call Transcript

Company to Hold R&D Day on Thursday, March 11, 2021 Company to Hold R&D Day on Thursday, March 11, 2021

Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021

An ugly board of directors skirmish came to an end.

Why Ziopharm Oncology Stock Is Soaring Today

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.

Ziopharm to Participate in Upcoming January Conferences

– Advances Eden BioCell's clinical program to validate Rapid Personalized Manufacturing (RPM) –

Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas

Investors need to pay close attention to Ziopharm (ZIOP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock?

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that it received the requisite number of written consents to add all three of its director candidates – Robert Postma, Jaime Vieser and Holger Weis – to the Company's Board of Directors (the “Board”). Although each member of WaterMill's slate received support f

WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology

Jaime Vieser and Holger Weis Elected to Board of Directors Jaime Vieser and Holger Weis Elected to Board of Directors

Ziopharm Comments on Consent Solicitation Results

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue another opportunity. The Company has initiated a search for a new Chief Financial Officer.

Ziopharm Oncology Announces Chief Financial Officer to Step Down

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) is waging in response to our consent solicitation. Robert Postma, principal and founder of WaterMill, commented: “This latest chapter of Ziopharm's low-road campaign only validates our view that the recent additions of Kevin Buchi and Mary Thistle to

WaterMill Asset Management Addresses Ziopharm Oncology's Latest Distortion and Recent Threat

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card

Ziopharm Comments on Delay of WaterMill's Stated Consent Deadline

Recommends A gainst E lecting WaterMill Nominee Jaime Vieser

Egan-Jones Recommends Against Electing Dissident's Full Slate of Nominees to Ziopharm Board

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below letter to shareholders. As a reminder, WaterMill is encouraging shareholders to consent to all of its proposals by voting on the WHITE consent card. We

WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology

Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation

Ziopharm Details Actions in Response to Shareholder Feedback

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy advisory firm, has endorsed its case for meaningful change at Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) and recommended shareholders vote for all five proposals on WaterMill's WHITE consent card. In particular, Glass Lewis supports the addition of the entire WaterMill slate – R

Glass Lewis Recommends Ziopharm Shareholders Vote on the WHITE Consent Card for All of WaterMill's Director Candidates and Proposals

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today responded to the low-road campaign that the incumbent Board of Directors (the “Board”) has apparently initiated in order to smear Holger Weis and misrepresent his more t

WaterMill Asset Management Refutes Ziopharm Oncology's Desperate, Low-Road Smear Campaign

ISS Acknowledges Ziopharm's Outperformance of its Peer Group During Chairman Scott Tarriff's Tenure

Ziopharm Comments on Institutional Shareholder Services' Recommendation to Reject WaterMill's Attempt to Remove Half of Ziopharm's Board of Directors

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy voting advisory firm, recommends shareholders vote for boardroom change on th

 ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management's WHITE Consent Card

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today released a new rebuttal presentation in response to the incumbent Board of Directors' (the “Board”) recent attempt to mislead shareholders and rewrite history regarding

News for ZIOPHARM Oncology Stock (ZIOP)